Product
ERAS-601
3 clinical trials
2 indications
Indication
Advanced or Metastatic Solid TumorsClinical trial
A Phase 1b Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Non-Small-Cell Lung CancerStatus: Completed, Estimated PCD: 2023-04-27
Clinical trial
A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-05-01